Portal de investigación
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Hernandez-Rivas, Jesus M.
- Calasanz, Maria J.
- Aventin, Anna
- Ferro, Maria T.
- Luno, Elisa
- Sanchez, Javier
- Vellenga, Edo
- Rayon, Chelo
- Milone, Gustavo
- de la Serna, Javier
- Rivas, Concha
- Gonzalez, Jose D.
- Tormo, Mar
- Amutio, Elena
- Gonzalez, Marcos
- Brunet, Salut
- Lowenberg, Bob
Grupos
Abstract
Background Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter. Design and Methods Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation. Results Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis. Conclusions The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.
Datos de la publicación
- ISSN/ISSNe:
- 0390-6078, 1592-8721
- Tipo:
- Article
- Páginas:
- 424-431
- Factor de Impacto:
- 1,864 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
HAEMATOLOGICA FERRATA STORTI FOUNDATION
Citas Recibidas en Web of Science: 59
Documentos
- No hay documentos
Filiaciones
Keywords
- acute promyelocytic leukemia; additional chromosomal abnormalities; prognostic factors; all-trans retinoic acid; anthracycline
Proyectos asociados
RED DE INVESTIGACION COOPERATIVA DE CANCER
RD06/0020/0031 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006
PROYECTO CAIBER
CAI08/01/0061 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
RED DE BIOBANCOS (BIOBANCOS)
RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
CREACION Y MEJORA DE INFRAESTRUCTURAS EN MEDICINA REGENERATIVA
Investigador Principal: FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA
PLE2009-0141 ACI-PLAN E . MINISTERIO DE CIENCIA E INNOVACION; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
ESTUDIO FASE I/II NACIONAL, ABIERTO, MULTICENTRICO, DE PANOBINOSTAT EN COMBINACION CON IDARRUBICINA Y CITARABINA EN PACIENTES DE EDAD IGUAL O SUPERIOR A 65 AÑOS CON LEUCEMIA MIELOBLASTICA AGUDA (LMA) DE NUEVO DIAGNOSTICO
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PANOBIDARA . 2009
ESTUDIO ALEATORIZADO, DOBLE-CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ROMIPLOSTIM EN EL TRATAMIENTO DE LA TROMBOCITOPENIA EN PACIENTES CON SINDROME MIELODISPLASICO (SMD) DE RIESGO BAJO O INTERMEDIO-1.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
20060198 . 2008
ENSAYO ABIERTO DE FASE III PARA EVALUAR LA SEGURIDAD,TOLERABILIDAD E INMUNOGENIA DE LA VACUNA ANTINEUMOCOCICA CONJUGADA TRIDECAVALENTE SEGUIDA DE LA VACUNA ANTINEUMOCOCICA POLISACARIDA DE 23 SEROTIPOS EN RECEPTORES DE TRASPLANTE ALOGENICO DE CELULAS GERMI NALES HEMATOPOYETICAS DE 2 O MAS AÑOS DE EDAD.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
6115A1-3003-WW . 2010
MANEJO CLINICO DE LA PURPURA TROMBOCITOPENICA IDIOPATICA CRONICA EN ESPAÑA
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
04107 . 2008
ESTUDIO OBSERVACIONAL EUROPEO DE DASATINIB (SPRYCEL) EN EL TRATAMIENTO DE PACIENTES CON LEUCEMIA MIELOIDE CRONICA, RESISTENTES E INTOLERANTES A IMATINIB
Investigador Principal: JESUS ANTONIO MARTINEZ DOMINGUEZ
CA180211 . 2009
Cita
Cervera J,Montesinos P,Hernandez JM,Calasanz MJ,Aventin A,Ferro MT,Luno E,Sanchez J,Vellenga E,Rayon C,Milone G,de la Serna J,Rivas C,Gonzalez JD,Tormo M,Amutio E,Gonzalez M,Brunet S,Lowenberg B,Sanz MA. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010. 95. (3):p. 424-431. IF:6,000. (1).